Cargando…
NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59
Cancer immunoediting drives the adaptation of tumor cells to host immune surveillance. Previously, we have demonstrated that immunoediting driven by cytotoxic T lymphocytes (CTLs) enriches NANOG(+) tumor cells with immune-refractory properties. Here, we found that CTL-mediated immune pressure trigge...
Autores principales: | Son, Sung Wook, Cho, Eunho, Cho, Hanbyoul, Woo, Seon Rang, Lee, Hyo-Jung, Oh, Se Jin, Kim, Suyeon, Kim, Jae-Hoon, Chung, Eun Joo, Chung, Joon-Yong, Kim, Min Gyu, Song, Kwon-Ho, Kim, Tae Woo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126891/ https://www.ncbi.nlm.nih.gov/pubmed/35606403 http://dx.doi.org/10.1038/s41598-022-12692-6 |
Ejemplares similares
-
Targeting the NANOG/HDAC1 axis reverses resistance to PD-1 blockade by reinvigorating the antitumor immunity cycle
por: Oh, Se Jin, et al.
Publicado: (2022) -
HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors
por: Song, Kwon-Ho, et al.
Publicado: (2020) -
NANOG regulates epithelial–mesenchymal transition via AMPK/mTOR signalling pathway in ovarian cancer SKOV‐3 and A2780 cells
por: Yun, Hee, et al.
Publicado: (2022) -
Far Beyond Cancer Immunotherapy: Reversion of Multi-Malignant Phenotypes of Immunotherapeutic-Resistant Cancer by Targeting the NANOG Signaling Axis
por: Oh, Se Jin, et al.
Publicado: (2020) -
API5 induces cisplatin resistance through FGFR signaling in human cancer cells
por: Jang, Han Sol, et al.
Publicado: (2017)